drugset / Trial / NCT01400503
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the long-term safety of siltuximab in patients with multicentric Castleman's disease (MCD).
Timeline
- Start
- 2011-04-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siltuximab | Monoclonal antibody | 11 mg/kg | Intravenous |